A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non- Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study

15350OSE2101C302-NCT06472245OpenA randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non- Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA studyOSE2101C302NCT06472245IndustrialAdultTreatmentIIIOtherLiu, StephenGeorgetown University Medical Center : Jeanette Crawford; Lombardi Comprehensive Cancer Center : Jeanette CrawfordThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS6888Jeanette CrawfordJeanette Crawford+1 202-687-0893crawfojg@georgetown.eduResearch Nursing Coordinator 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>